iShares Core MSCI China Index ETF(02801.HK) Rose 0.93% to 26.160
Newtimespace News, as of 10:36 on May 14, iShares Core MSCI China Index ETF(02801.HK) was quoted at HKD 26.160, up 0.93%. The ETF opened at HKD 26.200, with a high of HKD 26.480 and a low of HKD 26.140. The latest NAV per unit is HKD 25.957, with a premium rate of -0.14%. The asset size is approximately HKD 16.119 billion.
iShares Core MSCI China Index ETF(02801.HK) tracks the MSCI China Index, which is compiled and published by MSCI Inc. The index aims to comprehensively reflect the overall performance of China's listed companies. Its constituent coverage is broad, including A-shares and B-shares listed on the Shanghai and Shenzhen Stock Exchanges, H-shares, red chips, and P-chips listed on the Hong Kong Stock Exchange, as well as Chinese companies listed overseas. It serves as one of the key benchmarks reflecting the overall performance of China's stock market.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment